Emyria Ltd (ASX:EMD)'s Michael Winlo tells Proactive about the company's vision to expand its real world data assets for MDMA-assisted therapy trials with wearables monitoring. The drug development and care delivery company has partnered with Seattle-based Cydelic to incorporate its remote monitoring technology with its data platform and provide further insights before, during and after the clinical trial.
Emyria to adopt wearables monitoring tech for MDMA-assisted therapy trials
